GlobeNewswire Inc | Nov 11, 2020 08:00AM EST

November 11, 2020

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the Stifel Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference that are being held in November 2020.

Event: Stifel 2020 Virtual Healthcare ConferenceDate: Monday, November 16Time: 9:20 a.m. ET A webcast will be available at the ?Investors? section of theWebcast: Company?s website at www.avadel.com. A replay of the webcasts will be available on Avadel?s website for 90 days following the presentation. Event: Jefferies Virtual London Healthcare ConferenceDate: Wednesday, Nov. 18thTime: 6:45 p.m. GMT (1:45 p.m. ET) A webcast will be available at the ?Investors? section of theWebcast: Company?s website at www.avadel.com. A replay of the webcasts will be available on Avadel?s website for 90 days following the presentation.

About Avadel Pharmaceuticals plc:Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Companys primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Contacts:

Tom McHughChief Financial OfficerPhone: (636) 449-1843Email: tmchugh@avadel.com Tim McCarthyLifeSci Advisors, LLCPhone: (212) 915.2564Email: tim@lifesciadvisors.com